Investigational Drug Information for Eritoran
What is the development status for investigational drug Eritoran?
Eritoran is an investigational drug.
There have been 5 clinical trials for Eritoran.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 11th 2016.
The most common disease conditions in clinical trials are Hypersensitivity, Insulin Resistance, and Leukemia. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and Global Coalition for Adaptive Research.
Summary for Eritoran
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 305 |
| WIPO Patent Applications | 81 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 3 (2016-04-11) |
| Vendors | 15 |
Recent Clinical Trials for Eritoran
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Australian and New Zealand Intensive Care Research Centre | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Berry Consultants | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Global Coalition for Adaptive Research | Phase 4 |
Clinical Trial Summary for Eritoran
Top disease conditions for Eritoran
Top clinical trial sponsors for Eritoran
US Patents for Eritoran
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Eritoran Development Update and Market Projection: Clinical Status, Patent Position, and Commercial Outlook
Eritoran is a discontinued investigational Toll-like receptor 4 (TLR4) antagonist developed by Eisai for severe sepsis and septic shock. Its pivotal ACCESS trial failed to reduce 28-day all-cause mortality, and Eisai stopped clinical development in 2013. Eritoran has no FDA approval, no Orange Book listing, no commercial sales, and no credible near-term market forecast. Its commercial value is currently limited to possible research, licensing, or platform applications involving TLR4 biology.
What is Eritoran and how does it work?
Eritoran tetrasodium, also known as E5564, is a synthetic lipid A analog designed to block signaling through the lipopolysaccharide receptor complex formed by TLR4 and MD-2.
The mechanism was intended to reduce excessive innate immune activation caused by Gram-negative bacterial endotoxin. TLR4 activation triggers downstream inflammatory signaling, including NF-kB and mitogen-activated protein kinase pathways. In severe sepsis, the therapeutic premise was that blocking endotoxin-mediated signaling could reduce systemic inflammation, organ failure, and death.
Eritoran was administered intravenously. Its primary development target was adult patients with severe sepsis and septic shock, rather than a specific bacterial infection.
Eritoran development profile
| Attribute | Details |
|---|---|
| Active ingredient | Eritoran tetrasodium |
| Development code | E5564 |
| Developer | Eisai Co., Ltd. |
| Drug class | TLR4/MD-2 antagonist; synthetic lipid A analog |
| Route | Intravenous |
| Lead indication | Severe sepsis and septic shock |
| Pivotal study | ACCESS, Phase III |
| Regulatory status | Not approved |
| Commercial status | No marketed product |
| Development status | Discontinued |
| Primary clinical failure | No statistically significant reduction in 28-day all-cause mortality |
What happened in the Eritoran Phase III trial?
Eritoran failed the ACCESS Phase III study, the largest and most important clinical test of the program.
The randomized, double-blind, placebo-controlled trial enrolled 1,961 patients with severe sepsis. Patients received intravenous eritoran or placebo in addition to standard care. The primary endpoint was 28-day all-cause mortality.
The trial found no significant mortality benefit for eritoran. The 28-day mortality rate was 28.1% in the eritoran group and 26.9% in the placebo group. The odds ratio for death was not favorable to eritoran, and the study did not support further development in the broad severe-sepsis population (Opal et al., 2013).
ACCESS trial results
| Metric | Eritoran | Placebo |
|---|---|---|
| Patient population | Severe sepsis | Severe sepsis |
| Approximate enrollment | 1,000 | 961 |
| 28-day mortality | 28.1% | 26.9% |
| Primary endpoint | Not met | N/A |
| Regulatory consequence | No approval path established | N/A |
The result was commercially decisive because the program had already reached a large global Phase III trial. A successful study could have supported a broad hospital product with potential use across bacterial sepsis cases. The negative result removed the principal basis for regulatory filing.
When did Eritoran lose exclusivity and clinical momentum?
Eritoran lost commercial momentum after the ACCESS failure in 2013. Eisai reported that it would discontinue development following the negative Phase III results. The program did not advance into a confirmatory trial, a narrower biomarker-selected study, or an alternative regulatory filing.
The relevant timeline is:
| Year | Development event |
|---|---|
| 1990s-2000s | Preclinical and early clinical development of TLR4 antagonism |
| 2008 | Earlier clinical work evaluated eritoran in severe sepsis |
| 2010s | Phase III ACCESS study initiated and completed |
| 2013 | ACCESS results showed no mortality benefit |
| 2013 onward | Eisai discontinued further clinical development |
| Current status | No approval, no commercial launch, no active pivotal program |
Patent expiration must be distinguished from clinical discontinuation. Patent rights may have extended beyond the point at which clinical value was lost, but the public commercial record does not indicate an active eritoran product or a current branded market protected by those rights.
What is the FDA regulatory status of Eritoran?
Eritoran is not FDA approved. It does not have an approved indication, an established prescription label, or a U.S. marketing authorization.
There is no public basis for treating eritoran as an FDA-review-stage asset. The Phase III failure occurred before a successful New Drug Application review, and the program has not produced an approved product.
Regulatory status summary
| Regulatory item | Status |
|---|---|
| FDA approval | None |
| Approved indication | None |
| U.S. prescribing information | None |
| Orange Book listing | None identified |
| FDA exclusivity | None attached to an approved product |
| Biosimilar pathway | Not applicable |
| Generic pathway | Not applicable without an approved reference product |
Eritoran also does not fit the biosimilar framework. It is a synthetic small-molecule-like lipid analog rather than a therapeutic protein or other biologic subject to abbreviated biosimilar approval.
What patents protect Eritoran?
Eritoran was developed through a combination of compound, lipid A analog, formulation, and use-related intellectual property. Eisai and predecessor research organizations were associated with development and commercialization rights. The most important protection would have related to the chemical structure and pharmaceutical use of eritoran as a TLR4 antagonist.
The current commercial relevance of that estate is limited. There is no marketed reference product against which a generic challenger could file an ANDA, and no Orange Book patent listing creates an active regulatory barrier.
Patent categories associated with the program
| Patent category | Strategic purpose | Current commercial relevance |
|---|---|---|
| Composition of matter | Protect eritoran and related lipid A analogs | Likely limited by age, abandonment, or expiration |
| TLR4/MD-2 antagonism | Protect biological use of the compound | Limited without clinical development |
| Injectable formulation | Cover intravenous pharmaceutical compositions | No marketed product requiring protection |
| Method of treating sepsis | Protect clinical use | Commercial value reduced by failed Phase III efficacy |
| Manufacturing processes | Protect synthesis, purification, or salt forms | Potentially relevant to research supply, not a commercial drug |
A precise patent-by-patent freedom-to-operate opinion cannot be inferred from the clinical record alone. The absence of an Orange Book listing is clear, but it does not establish that every historical patent has expired or that no foreign rights remain.
Does Eritoran face Paragraph IV challenges or generic entry risk?
No active Paragraph IV litigation or generic launch scenario is commercially material for eritoran.
Paragraph IV challenges normally arise when a generic applicant seeks FDA approval for an approved small-molecule reference drug while certifying that listed patents are invalid, unenforceable, or not infringed. Eritoran has no approved U.S. reference product and no Orange Book patent estate supporting that process.
Generic entry scenarios
| Scenario | Probability based on current status | Commercial effect |
|---|---|---|
| ANDA launch against an approved eritoran product | Negligible | None |
| Paragraph IV patent litigation | Negligible | None identified |
| Compounded or research-use supply | Possible but noncommercial | Limited |
| Revival by a new sponsor | Low | Would require new clinical evidence |
| New TLR4 antagonist competing with eritoran | More plausible | Could validate mechanism without reviving eritoran |
The primary competitive risk is not generic substitution. It is replacement by newer immunomodulatory approaches that can identify the patients most likely to benefit.
What patent litigation or settlement agreements affect Eritoran?
No material public patent litigation, settlement agreement, or generic-entry settlement is associated with an approved eritoran product.
The principal legal-commercial event was the termination of the development program after the ACCESS results. That event differs from a patent settlement or regulatory exclusivity dispute. There is no identified settlement that delayed generic entry or transferred a marketed-product franchise.
How strong is the Eritoran patent estate?
The estate may have been technically meaningful during the development period but is commercially weak today.
Historical strengths
- Eritoran was based on a defined molecular structure rather than an unprotected biological concept.
- Composition and formulation rights could have created barriers during the patent term.
- Intravenous hospital use could have supported method-of-treatment claims.
- Eisai had the resources to prosecute and enforce a global pharmaceutical estate.
Current weaknesses
- The principal indication failed in Phase III.
- No approved label supports method-of-use enforcement.
- No Orange Book listing creates an FDA-linked patent stay.
- A competitor can pursue a differentiated TLR4 mechanism or a biomarker-defined population.
- Commercial value depends on new clinical validation rather than legacy exclusivity.
Patent strength is therefore separate from asset value. Even a surviving patent claim would have limited economic significance without proof that eritoran improves outcomes in a commercially addressable population.
What is the competitive landscape for TLR4 antagonists?
Eritoran entered a difficult sepsis market. Sepsis is biologically heterogeneous, rapidly progressive, and treated with antibiotics, source control, fluids, vasopressors, respiratory support, and organ replacement. A single immune-pathway inhibitor must show benefit across variable pathogens, disease stages, comorbidities, and treatment settings.
Other TLR4-directed programs have included TAK-242, also known as resatorvid, and antibody or small-molecule approaches targeting endotoxin signaling. These programs have not established a commercially successful TLR4 drug for broad sepsis treatment.
Competitive factors
- Heterogeneous disease biology. Sepsis is not driven by one uniform inflammatory pathway.
- Timing risk. TLR4 blockade may require administration before irreversible organ injury.
- Patient selection. Broad enrollment may dilute activity in patients with endotoxin-driven disease.
- Clinical endpoint risk. Mortality studies require large populations and are vulnerable to changes in standard care.
- Hospital adoption. A new therapy would need clear incremental value over established supportive treatment.
Eritoran’s failure does not prove that all TLR4 antagonists lack activity. It does show that broad, unselected use in severe sepsis did not produce a commercially sufficient clinical outcome.
What is the market projection for Eritoran?
The current market projection for eritoran is effectively zero in approved-drug revenue.
| Market category | Current projection |
|---|---|
| U.S. branded sales | $0 |
| Global commercial sales | $0 |
| FDA-approved hospital use | $0 |
| Generic erosion exposure | None |
| Near-term licensing value | Low and speculative |
| Research or platform value | Possible but limited |
A revived eritoran program would require a new sponsor to fund additional translational work, identify a responsive patient subgroup, and conduct clinical trials capable of overcoming the negative ACCESS result. That pathway would likely require a new development strategy rather than a direct continuation of the former program.
Potential addressable market if successfully revived
The historical commercial opportunity was large because severe sepsis is treated in intensive-care units worldwide. The eligible population would have included patients with severe infection, organ dysfunction, and high short-term mortality. A successful therapy could have generated substantial hospital sales, especially if it reduced mortality or shortened intensive-care utilization.
That opportunity is no longer a realistic base-case forecast. Any valuation should assign value to the mechanism or intellectual property platform, not to expected eritoran product revenue.
How does Eritoran compare with approved sepsis therapies?
Eritoran has no approved therapeutic position. Its comparison with current sepsis treatment is therefore mechanistic rather than commercial.
| Treatment category | Role in sepsis care | Eritoran comparison |
|---|---|---|
| Antibiotics | Treat underlying infection | Eritoran does not eradicate pathogens |
| Source control | Removes infected tissue or devices | Eritoran has no source-control effect |
| Vasopressors | Support blood pressure | Eritoran does not directly restore hemodynamics |
| Fluids and organ support | Stabilize failing organs | Eritoran was intended to modify inflammation |
| TLR4 blockade | Investigational immunomodulation | Eritoran was the leading failed broad-sepsis example |
The absence of an approved immunomodulatory TLR4 antagonist leaves the commercial category open, but it also reflects repeated difficulty converting inflammatory biology into mortality benefit.
Key Takeaways
- Eritoran, or E5564, is a discontinued Eisai TLR4/MD-2 antagonist.
- The Phase III ACCESS trial enrolled 1,961 patients and failed its 28-day mortality endpoint.
- Eisai stopped development after the 2013 results.
- Eritoran has no FDA approval, no Orange Book listing, and no commercial sales.
- Biosimilar risk is not applicable, and Paragraph IV generic risk is not commercially material.
- Historical composition, formulation, and method-of-use patents may have protected the program, but legacy patent rights have little value without clinical efficacy.
- The current market projection is effectively $0 for branded or generic revenue.
- Any residual value lies in research rights, TLR4 biology, or a possible future biomarker-selected development strategy.
FAQs About Eritoran
Is eritoran still in clinical development?
No. The program was discontinued after the negative ACCESS Phase III trial.
Did eritoran receive FDA breakthrough therapy or approval?
No. Eritoran did not receive FDA approval and has no approved clinical indication.
Can a generic company launch eritoran?
There is no approved U.S. eritoran reference product for an ANDA-based generic launch. Research-use manufacture is possible, but that is different from commercial generic entry.
Was eritoran effective against endotoxin?
Eritoran was designed to block endotoxin signaling through TLR4 and MD-2, but this mechanism did not translate into a mortality benefit in the broad severe-sepsis population studied in ACCESS.
Could eritoran be revived for a narrower patient population?
A revival is theoretically possible but would require new evidence, patient-selection strategy, and clinical trials. The historical Phase III failure makes a broad-label redevelopment unlikely.
References
-
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., Jauregui, L., Krell, K., Wanner, A., Feissel, M., Bouchard, A., Martin, C., Pachl, J., Trocóniz, I. F., Ugarte, H., ... Eisai. (2013). Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. New England Journal of Medicine, 368(16), 2505-2515. https://doi.org/10.1056/NEJMoa1205139
-
ClinicalTrials.gov. (n.d.). A study of eritoran tetrasodium in patients with severe sepsis and shock: ACCESS trial. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Eisai Co., Ltd. (2013). Eisai announces results from Phase III ACCESS trial of eritoran tetrasodium in severe sepsis. Corporate clinical-development communications.
More… ↓
